| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| 100mg | |||
| Other Sizes |
| Targets |
mTRP-2 (180-188) targets the immune system, specifically serving as an epitope for cytotoxic T lymphocytes (CTLs). The peptide is derived from mouse tyrosinase-related protein 2 (TRP-2), a melanocyte differentiation antigen. It is recognized by anti-B16 CTLs as the major reactive epitope within TRP-2. TRP-2 is involved in melanin biosynthesis and is a tumor-associated antigen in melanoma. The peptide's interaction with MHC class I molecules enables CTL recognition and activation.
|
|---|---|
| ln Vitro |
In vitro, mTRP-2 (180-188) is used as a peptide antigen to stimulate and study CTL responses against TRP-2-expressing cells. It is recognized by anti-B16 CTLs as the major reactive epitope within TRP-2. The peptide can be loaded onto antigen-presenting cells expressing the appropriate MHC class I molecule and used to activate TRP-2-specific CTLs. T cell activation is measured by assessing proliferation, cytokine production, and cytotoxicity. The peptide is a valuable tool for studying T cell responses to melanoma antigens.
|
| ln Vivo |
In vivo studies of mTRP-2 (180-188) are focused on its use as a peptide vaccine or immunotherapeutic agent in mouse models of melanoma. The peptide can be administered to mice to induce or enhance TRP-2-specific CTL responses, leading to anti-tumor immunity. It is identified as the major reactive epitope within TRP-2 recognized by anti-B16 CTLs. Further in vivo studies are needed to evaluate its efficacy as a cancer vaccine and to optimize immunization protocols.
|
| Enzyme Assay |
For in vitro peptide-MHC binding assays, mTRP-2 (180-188) can be evaluated using MHC class I binding assays to measure its affinity for the appropriate MHC molecule. The peptide is incubated with MHC molecules (either purified or expressed on cells) and binding is quantified using conformation-specific antibodies or by measuring MHC stabilization on the cell surface. Peptide-MHC tetramers can be generated using this peptide for staining antigen-specific T cells. Standard assay conditions include physiological buffer systems with appropriate pH.
|
| Cell Assay |
For in vitro cellular experiments, mTRP-2 (180-188) is used in T cell activation assays. Antigen-presenting cells expressing the appropriate MHC class I molecule are loaded with the peptide and co-cultured with CTLs from mice immunized against TRP-2. T cell activation is measured by assessing proliferation (using [3H]-thymidine incorporation or CFSE dilution), cytokine production (by ELISA or intracellular cytokine staining), and cytotoxicity (using ⁵¹Cr release assays or other cytotoxicity assays). The peptide's ability to stimulate TRP-2-specific CTLs is quantified.
|
| Animal Protocol |
For in vivo animal experiments, mTRP-2 (180-188) is administered to mice to induce or modulate TRP-2-specific CTL responses. The peptide can be injected subcutaneously, intradermally, or intraperitoneally, often with adjuvant to enhance immunogenicity. Alternatively, dendritic cells loaded with the peptide can be used for immunization. Immune responses are evaluated by measuring CTL activity, cytokine production, and tumor growth inhibition in melanoma models. Animal studies should follow appropriate ethical guidelines.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties of mTRP-2 (180-188) are not relevant, as it is used as a research peptide for immunological studies rather than a therapeutic agent. As a peptide with a molecular weight of 1175.33, it would be expected to have low oral bioavailability and rapid clearance by proteases. When administered systemically, the peptide would likely be rapidly degraded. For immunization studies, adjuvants are used to enhance its immunogenicity and prolong its presentation. The peptide should be stored appropriately to maintain stability.
|
| Toxicity/Toxicokinetics |
Toxicological data for mTRP-2 (180-188) are limited, as it is a research peptide used in immunological studies. As a peptide derived from a self-protein, it is generally considered to have low toxicity at the concentrations used for research. However, when administered with strong adjuvants, it can induce robust immune responses that may lead to inflammation. Standard toxicological assessments would include evaluation of immune-mediated adverse effects. As with all research peptides, appropriate safety precautions should be taken when handling this compound.
|
| Additional Infomation |
mTRP-2 (180-188) is a research peptide used to study T cell responses to melanoma antigens. No clinical trials or regulatory approvals have been reported for this peptide as a therapeutic agent. It is available from various peptide suppliers for research purposes only. The peptide is a murine TRP-2-derived peptide corresponding to residues 180-188 and is identified as the major reactive epitope within TRP-2 recognized by anti-B16 CTLs.
|
| Molecular Formula |
C61H78N10O14
|
|---|---|
| Molecular Weight |
1175.33063554764
|
| Exact Mass |
1174.569
|
| CAS # |
219312-69-3
|
| PubChem CID |
9963581
|
| Appearance |
White to off-white solid powder
|
| LogP |
2.4
|
| Hydrogen Bond Donor Count |
14
|
| Hydrogen Bond Acceptor Count |
15
|
| Rotatable Bond Count |
32
|
| Heavy Atom Count |
85
|
| Complexity |
2230
|
| Defined Atom Stereocenter Count |
9
|
| SMILES |
CC(C)C[C@@H](C(=O)O)NC(=O)[C@H](CC1=CNC2=CC=CC=C21)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC3=CC=CC=C3)NC(=O)[C@H](CC4=CC=CC=C4)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CC5=CC=C(C=C5)O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CO)N
|
| InChi Key |
DONZTCDLTFZGMF-UKTPXDMFSA-N
|
| InChi Code |
InChI=1S/C61H78N10O14/c1-33(2)25-49(61(84)85)69-56(79)47(29-39-31-63-43-20-14-13-19-41(39)43)68-60(83)52(35(5)6)71-58(81)46(27-37-17-11-8-12-18-37)65-54(77)44(26-36-15-9-7-10-16-36)64-57(80)48(30-50(74)75)66-55(78)45(28-38-21-23-40(73)24-22-38)67-59(82)51(34(3)4)70-53(76)42(62)32-72/h7-24,31,33-35,42,44-49,51-52,63,72-73H,25-30,32,62H2,1-6H3,(H,64,80)(H,65,77)(H,66,78)(H,67,82)(H,68,83)(H,69,79)(H,70,76)(H,71,81)(H,74,75)(H,84,85)/t42-,44-,45-,46-,47-,48-,49-,51-,52-/m0/s1
|
| Chemical Name |
(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-amino-3-hydroxypropanoyl]amino]-3-methylbutanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-3-carboxypropanoyl]amino]-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-3-methylbutanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-4-methylpentanoic acid
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture and light. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ≥ 50 mg/mL (~42.54 mM)
H2O : ~33.33 mg/mL (~28.36 mM) |
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 0.8508 mL | 4.2541 mL | 8.5082 mL | |
| 5 mM | 0.1702 mL | 0.8508 mL | 1.7016 mL | |
| 10 mM | 0.0851 mL | 0.4254 mL | 0.8508 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
